Insider Trading Alert - DXCM, FDP And OCRX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 6, 2015, 74 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.44 to $8,899,995.42.

Highlighted Stocks Traded by Insiders:

DexCom (DXCM) - FREE Research Report

Sayer Kevin R, who is President & CEO at DexCom, sold 25,000 shares at $68.01 on May 6, 2015. Following this transaction, the President & CEO owned 407,360 shares meaning that the stake was reduced by 5.78% with the 25,000-share transaction.

The shares most recently traded at $67.12, down $0.89, or 1.33% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 27,698
  • 24-Week # shares sold: 39,698

The average volume for DexCom has been 717,600 shares per day over the past 30 days. DexCom has a market cap of $5.2 billion and is part of the health care sector and health services industry. Shares are up 20.25% year-to-date as of the close of trading on Wednesday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently, there are 9 analysts who rate DexCom a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings rates DexCom as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Fresh Del Monte Produce (FDP) - FREE Research Report

El-Naffy Hani, who is President and COO at Fresh Del Monte Produce, sold 5,932 shares at $37.00 on May 6, 2015. Following this transaction, the President and COO owned 0 shares meaning that the stake was reduced by 100% with the 5,932-share transaction.

The shares most recently traded at $36.60, down $0.40, or 1.09% since the insider transaction. Historical insider transactions for Fresh Del Monte Produce go as follows:

  • 4-Week # shares sold: 3,429
  • 12-Week # shares sold: 7,450
  • 24-Week # shares sold: 7,450

The average volume for Fresh Del Monte Produce has been 237,600 shares per day over the past 30 days. Fresh Del Monte Produce has a market cap of $1.9 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 8.58% year-to-date as of the close of trading on Wednesday.

Fresh Del Monte Produce Inc. produces, markets, and distributes fresh and fresh-cut fruit and vegetables worldwide. The stock currently has a dividend yield of 1.37%. The company has a P/E ratio of 15.9. Currently, there are no analysts who rate Fresh Del Monte Produce a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FDP - FREE

TheStreet Quant Ratings rates Fresh Del Monte Produce as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Fresh Del Monte Produce Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ocera Therapeutics (OCRX) - FREE Research Report

Grais Linda S, who is President and CEO at Ocera Therapeutics, bought 30,000 shares at $3.73 on May 6, 2015. Following this transaction, the President and CEO owned 40,000 shares meaning that the stake was boosted by 300% with the 30,000-share transaction.

Aggarwal Gaurav, who is Chief Business Officer at Ocera Therapeutics, bought 7,500 shares at $3.62 on May 6, 2015. Following this transaction, the Chief Business Officer owned 10,000 shares meaning that the stake was boosted by 300% with the 7,500-share transaction.

Byrnes Michael, who is CFO and Treasurer at Ocera Therapeutics, bought 2,500 shares at $3.61 on May 6, 2015. Following this transaction, the CFO and Treasurer owned 6,500 shares meaning that the stake was boosted by 62.5% with the 2,500-share transaction.

The shares most recently traded at $3.97, up $0.36, or 9.07% since the insider transaction. Historical insider transactions for Ocera Therapeutics go as follows:

  • 4-Week # shares bought: 2,000
  • 12-Week # shares bought: 2,000
  • 24-Week # shares bought: 2,000

The average volume for Ocera Therapeutics has been 139,200 shares per day over the past 30 days. Ocera Therapeutics has a market cap of $70.3 million and is part of the health care sector and drugs industry. Shares are down 44.11% year-to-date as of the close of trading on Wednesday.

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. Currently, there are 2 analysts who rate Ocera Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OCRX - FREE

TheStreet Quant Ratings rates Ocera Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full Ocera Therapeutics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings